Viridian Therapeutics (NASDAQ:VRDN) Shares Gap Down After Analyst Downgrade

Viridian Therapeutics, Inc. (NASDAQ:VRDN) shares gapped down prior to trading on Monday after The Goldman Sachs Group lowered their price target on the stock from $41.00 to $36.00. The stock had previously closed at $27.39, but opened at $17.00. The Goldman Sachs Group currently has a buy rating on the stock. Viridian Therapeutics shares last traded at $18.1620, with a volume of 4,451,127 shares trading hands.

A number of other analysts have also commented on the company. William Blair assumed coverage on Viridian Therapeutics in a report on Wednesday, December 3rd. They issued an “outperform” rating for the company. Truist Financial dropped their price objective on Viridian Therapeutics from $41.00 to $40.00 and set a “buy” rating on the stock in a research report on Thursday, January 8th. Royal Bank Of Canada reduced their price objective on Viridian Therapeutics from $45.00 to $42.00 and set an “outperform” rating for the company in a report on Friday, February 27th. Wall Street Zen lowered Viridian Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Finally, UBS Group started coverage on shares of Viridian Therapeutics in a research note on Wednesday, January 7th. They set a “buy” rating and a $50.00 target price on the stock. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $39.21.

Viridian Therapeutics News Roundup

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: REVEAL‑1 Phase 3 topline: The trial for elegrobart met its primary endpoint (statistically significant proptosis responder rates vs. placebo), confirming efficacy signals for the subcutaneous antibody. This is a fundamental clinical positive for Viridian’s lead program. BusinessWire release
• Neutral Sentiment: HC Wainwright kept a “Buy” rating and set a $22 price target while adjusting its FY2026 and quarterly EPS forecasts modestly (Q1/Q2/Q4 and FY estimates were nudged lower). The firm’s maintained Buy reduces some downside narrative but the lower target reflects more conservative modeling. (HC Wainwright research note)
• Negative Sentiment: Big investor reaction and heavy selling: multiple outlets report a large share decline (over 30% intraday; ~41% pre-market in some reports) despite the positive topline — suggesting the market was either disappointed by aspects of the readout, worried about commercialization prospects, or reacting to revised expectations. MSN coverage
• Negative Sentiment: Analyst price‑target cuts and re-ratings: Several brokers reduced targets or reset views after the data — HC Wainwright cut its target to $22, Wells Fargo to $20 (equal weight), Needham to $32, Wedbush to $37, and Goldman trimmed its target to $36 — increasing near-term downward pressure on the stock. Benzinga roundup
• Negative Sentiment: Follow‑on coverage highlighting the selloff and market confusion: multiple stories (Proactive, Investing.com, Bioworld) note the stock “tumbled despite trial success,” signaling that headlines and investor interpretation of the readout — not just the data itself — are driving volatility. Proactive article

Institutional Investors Weigh In On Viridian Therapeutics

A number of hedge funds have recently modified their holdings of the business. Avoro Capital Advisors LLC bought a new stake in shares of Viridian Therapeutics during the 4th quarter valued at $46,680,000. Seven Fleet Capital Management LP bought a new position in Viridian Therapeutics in the 4th quarter worth $456,000. Virtu Financial LLC purchased a new position in Viridian Therapeutics during the fourth quarter valued at $531,000. Invesco Ltd. lifted its position in Viridian Therapeutics by 127.1% during the fourth quarter. Invesco Ltd. now owns 183,468 shares of the company’s stock valued at $5,710,000 after purchasing an additional 102,676 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in Viridian Therapeutics during the fourth quarter valued at about $1,464,000.

Viridian Therapeutics Stock Up 5.6%

The company has a quick ratio of 12.65, a current ratio of 12.65 and a debt-to-equity ratio of 0.08. The company has a fifty day simple moving average of $29.16 and a 200-day simple moving average of $27.89. The firm has a market cap of $2.00 billion, a P/E ratio of -5.95 and a beta of 1.00.

Viridian Therapeutics (NASDAQ:VRDN) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.18). The company had revenue of $0.13 million during the quarter, compared to the consensus estimate of $15.75 million. Viridian Therapeutics had a negative return on equity of 83.25% and a negative net margin of 483.57%. On average, equities analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.